# MimiVax

> Clinical-stage immuno-oncology company developing SurVaxM cancer vaccine; Roswell Park spinout.

## Why it is interesting

Buffalo Roswell Park spinout commercializing SurVaxM, a survivin-targeted vaccine in Phase 2b for glioblastoma — nearly $25M raised from local capital, angels, and brain-tumor philanthropy rather than a classic Silicon Valley syndicate.

## Profile

- **Stage:** other
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech
- **Coverage:** full
- **Last updated:** 2026-07-26

## Key facts

- Founded 2012 as Roswell Park Comprehensive Cancer Center spinout (Buffalo, NY)
- Lead asset SurVaxM: survivin-targeted vaccine; Phase 2b program in newly diagnosed glioblastoma
- Nearly $25M raised (company-disclosed) from Buffalo Capital Partners, Varia Ventures, Fosun Pharma, NBTS/BTIF, Sontag, MEDA Angels, Tech Coast Angels, privates, and Roswell Park
- Jan 2024: additional investments from Brain Tumor Investment Fund, Sontag Innovation Fund, MEDA Angels, Varia Ventures to support Phase 2b and commercialization prep
- No Silicon Valley fund IDs in our directory for this syndicate — investors[] left empty by design

## Related articles

- https://venturecapitaltracker.com/buffalo-startups-and-vc-firms-2026

---
Source: https://venturecapitaltracker.com/startup/mimivax